Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

July 22, 2019

Study Completion Date

May 17, 2023

Conditions

Breast Ductal Carcinoma In Situ

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nelipepimut-S Plus GM-CSF Vaccine

Given ID

BIOLOGICAL

Sargramostim

Given ID

PROCEDURE

Surgical Procedure

Undergo surgery

Trial Locations (4)

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

Thomas Jefferson University Hospital, Philadelphia

M D Anderson Cancer Center, Houston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02636582 - Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | Biotech Hunter | Biotech Hunter